C5 and paroxysmal nocturnal hemoglobinuria: C5 monoclonal antibody drugs such as eculizumab and ravulizumab have been approved for PNH and aHUS [103,104], whereas cemdisiran, a GalNAc-siRNA targeting the C5 gene, is in a phase 2 clinical trial [105,106].